227. オスラー病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
2010 - EUCTR2009-018049-19-AT Austria;
Avastin
Hospices Civils de Lyon
2014 - EUCTR2013-004204-19-FR France;
Bevacizumab
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
2008 - EUCTR2010-020545-26-IT Italy;
Hanny Al-Samkari, MD
2020 Phase 2 NCT04404881 United States;
Hospices Civils de Lyon
2017 Phase 3 NCT03227263 France;
2014 Phase 2/Phase 3 NCT02106520 France;
2011 Phase 1 NCT01507480 France;
James Gossage
2011 Phase 2 NCT01408030 United States;
Medical University of Vienna
2011 Phase 2 NCT01314274 Austria;
Shandong Provincial ENT Hospital
2021 Phase 4 ChiCTR2100043253 China;
Stanford University
2014 Phase 4 NCT02389959 United States;
University of California, San Diego
2009 Phase 2 NCT01397695 United States;
Bevacuzimab spray
University Hospital, Caen
2014 Phase 1/Phase 2 NCT02157987 France;
Blood samples
Centre Hospitalier Universitaire Dijon
2018 - NCT03572556 France;
Dicynone
Asociación HHT España
2017 Phase 2;Phase 4 EUCTR2016-003982-24-ES Spain;
Doxycycline Hyclate
Unity Health Toronto
2018 Phase 2 NCT03397004 Canada;
EMEA/H/C/000712
St. Antonius Hospital
2019 Phase 2 EUCTR2019-003585-40-NL Netherlands;
Estriol
James Gossage
2011 Phase 2 NCT01408030 United States;
Ferrous sulphate 200mg oral tablet
Imperial College London
2013 - NCT01908543 United Kingdom;
Floseal
St. Michael's Hospital, Toronto
2015 - NCT02638012 Canada;
Gold
Beijing Institute of Otolaryngology
2018 Phase 0 ChiCTR1900027420 China;
Itraconazole
St. Antonius Ziekenhuis
2018 Phase 2 EUCTR2017-003272-31-NL Netherlands;
Mupirocin
Hospital Italiano de Buenos Aires
2017 Phase 3 NCT02963129 Argentina;
NaCl
Medical University of Vienna
2011 Phase 2 NCT01314274 Austria;
Nintedanib 150 mg and 100 mg soft capsules
Hospices Civils de Lyon
2020 Phase 2 NCT03954782 France;
Nintédanib
Hospices Civils de Lyon
2019 Phase 2 EUCTR2019-002593-31-FR France;
OCTREOTIDE ACETATE
Radboudumc
2020 Phase 3 EUCTR2018-004179-11-DE France;Germany;Italy;Netherlands;United Kingdom;
OCTREOTIDE ACETATO
RADBOUD UNIVERSITY MEDICAL CENTER
2021 Phase 3 EUCTR2018-004179-11-IT Denmark;France;Germany;Italy;Netherlands;United Kingdom;
OFEV
Hospices Civils de Lyon
2019 Phase 2 EUCTR2019-002593-31-FR France;
Octreotide
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004327 -
Octreotide LAR
Radboud University
2016 Phase 2 NCT02874326 Netherlands;
Octreotide a azione pronta 0,
RADBOUD UNIVERSITY MEDICAL CENTER
2021 Phase 3 EUCTR2018-004179-11-IT Denmark;France;Germany;Italy;Netherlands;United Kingdom;
PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
2010 - EUCTR2009-018049-19-AT Austria;
Pazopanib
Cure HHT
2019 Phase 2/Phase 3 NCT03850964 -
2019 Phase 1/Phase 2 NCT03850730 -
Pegylated Interferon Alpha2b
Mayo Clinic
2007 Phase 2 NCT00588146 United States;
Pomalidomide
The Cleveland Clinic
2015 Phase 1 NCT02287558 United States;
Pomalidomide Oral Product
The Cleveland Clinic
2019 Phase 2 NCT03910244 United States;
Propranolol treatment
University Hospital, Bordeaux
2020 Phase 3 NCT04113187 France;
RVG 18236
Radboud University Medical Center
2016 Phase 2 EUCTR2016-001340-19-NL Netherlands;
Ranibizumab
University of California, San Diego
2011 Phase 1 NCT01406639 United States;
SUB16402MIG
HOSPICES CIVILS DE LYON
2009 - EUCTR2008-006755-44-FR France;
Sandostatin LAR
Radboud University Medical Center
2016 Phase 2 EUCTR2016-001340-19-NL Netherlands;
Sclerotherapy
University of Minnesota
2011 Phase 1/Phase 2 NCT01408732 United States;
Sodium chloride
Hospices Civils de Lyon
2017 Phase 3 NCT03227263 France;
Soy protein isolate
National Center for Research Resources (NCRR)
1996 Phase 3 NCT00004654 -
Sporanox
St. Antonius Ziekenhuis
2018 Phase 2 EUCTR2017-003272-31-NL Netherlands;
Sterile saline
James Gossage
2011 Phase 2 NCT01408030 United States;
Submucosal Bevacizumab
University of California, San Diego
2010 Phase 2 NCT01402531 United States;
THALIDOMIDE CELGENE*28CPS
OSPEDALE POLICLINICO S. MATTEO
2011 Phase 2 EUCTR2011-004096-36-IT Italy;
TIMOLOL MALEATE
Hospices Civils de Lyon
2015 Phase 2 EUCTR2015-000385-55-FR France;
Tacrolimus (Advagraf)
St. Antonius Hospital
2019 Phase 2 EUCTR2019-003585-40-NL Netherlands;
Tacrolimus capsule (low-dose)
Unity Health Toronto
2020 Phase 2 NCT04646356 Canada;
Tamoxifen
Rabin Medical Center
2005 Phase 2 NCT00375622 Israel;
Thalidomide
IRCCS Policlinico S. Matteo
2011 Phase 2 NCT01485224 Italy;
Northport Veterans Affairs Medical Center
2006 Phase 2 NCT00389935 United States;
Timolol Alcon collyre
Hospices Civils de Lyon
2015 Phase 2 EUCTR2015-000385-55-FR France;
Timolol Gel
Washington University School of Medicine
2019 Phase 2 NCT04139018 United States;
Timolol nasal spray
Hospices Civils de Lyon
2015 Phase 2 NCT02484716 France;
Topical timolol maleate
Unity Health Toronto
2013 - NCT01752049 Canada;
Tranexamic acid
University Hospital, Saarland
2002 Phase 3 NCT01031992 Germany;
Vit D
St. Paul's Hospital, Canada
2018 Phase 2 NCT03981562 Canada;
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
2010 - EUCTR2009-018049-19-AT Austria;
Avastin
Hospices Civils de Lyon
2014 - EUCTR2013-004204-19-FR France;
Bevacizumab
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
2008 - EUCTR2010-020545-26-IT Italy;
Hanny Al-Samkari, MD
2020 Phase 2 NCT04404881 United States;
Hospices Civils de Lyon
2017 Phase 3 NCT03227263 France;
2014 Phase 2/Phase 3 NCT02106520 France;
2011 Phase 1 NCT01507480 France;
James Gossage
2011 Phase 2 NCT01408030 United States;
Medical University of Vienna
2011 Phase 2 NCT01314274 Austria;
Shandong Provincial ENT Hospital
2021 Phase 4 ChiCTR2100043253 China;
Stanford University
2014 Phase 4 NCT02389959 United States;
University of California, San Diego
2009 Phase 2 NCT01397695 United States;
Bevacuzimab spray
University Hospital, Caen
2014 Phase 1/Phase 2 NCT02157987 France;
Blood samples
Centre Hospitalier Universitaire Dijon
2018 - NCT03572556 France;
Dicynone
Asociación HHT España
2017 Phase 2;Phase 4 EUCTR2016-003982-24-ES Spain;
Doxycycline Hyclate
Unity Health Toronto
2018 Phase 2 NCT03397004 Canada;
EMEA/H/C/000712
St. Antonius Hospital
2019 Phase 2 EUCTR2019-003585-40-NL Netherlands;
Estriol
James Gossage
2011 Phase 2 NCT01408030 United States;
Ferrous sulphate 200mg oral tablet
Imperial College London
2013 - NCT01908543 United Kingdom;
Floseal
St. Michael's Hospital, Toronto
2015 - NCT02638012 Canada;
Gold
Beijing Institute of Otolaryngology
2018 Phase 0 ChiCTR1900027420 China;
Itraconazole
St. Antonius Ziekenhuis
2018 Phase 2 EUCTR2017-003272-31-NL Netherlands;
Mupirocin
Hospital Italiano de Buenos Aires
2017 Phase 3 NCT02963129 Argentina;
NaCl
Medical University of Vienna
2011 Phase 2 NCT01314274 Austria;
Nintedanib 150 mg and 100 mg soft capsules
Hospices Civils de Lyon
2020 Phase 2 NCT03954782 France;
Nintédanib
Hospices Civils de Lyon
2019 Phase 2 EUCTR2019-002593-31-FR France;
OCTREOTIDE ACETATE
Radboudumc
2020 Phase 3 EUCTR2018-004179-11-DE France;Germany;Italy;Netherlands;United Kingdom;
OCTREOTIDE ACETATO
RADBOUD UNIVERSITY MEDICAL CENTER
2021 Phase 3 EUCTR2018-004179-11-IT Denmark;France;Germany;Italy;Netherlands;United Kingdom;
OFEV
Hospices Civils de Lyon
2019 Phase 2 EUCTR2019-002593-31-FR France;
Octreotide
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004327 -
Octreotide LAR
Radboud University
2016 Phase 2 NCT02874326 Netherlands;
Octreotide a azione pronta 0,
RADBOUD UNIVERSITY MEDICAL CENTER
2021 Phase 3 EUCTR2018-004179-11-IT Denmark;France;Germany;Italy;Netherlands;United Kingdom;
PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
2010 - EUCTR2009-018049-19-AT Austria;
Pazopanib
Cure HHT
2019 Phase 2/Phase 3 NCT03850964 -
2019 Phase 1/Phase 2 NCT03850730 -
Pegylated Interferon Alpha2b
Mayo Clinic
2007 Phase 2 NCT00588146 United States;
Pomalidomide
The Cleveland Clinic
2015 Phase 1 NCT02287558 United States;
Pomalidomide Oral Product
The Cleveland Clinic
2019 Phase 2 NCT03910244 United States;
Propranolol treatment
University Hospital, Bordeaux
2020 Phase 3 NCT04113187 France;
RVG 18236
Radboud University Medical Center
2016 Phase 2 EUCTR2016-001340-19-NL Netherlands;
Ranibizumab
University of California, San Diego
2011 Phase 1 NCT01406639 United States;
SUB16402MIG
HOSPICES CIVILS DE LYON
2009 - EUCTR2008-006755-44-FR France;
Sandostatin LAR
Radboud University Medical Center
2016 Phase 2 EUCTR2016-001340-19-NL Netherlands;
Sclerotherapy
University of Minnesota
2011 Phase 1/Phase 2 NCT01408732 United States;
Sodium chloride
Hospices Civils de Lyon
2017 Phase 3 NCT03227263 France;
Soy protein isolate
National Center for Research Resources (NCRR)
1996 Phase 3 NCT00004654 -
Sporanox
St. Antonius Ziekenhuis
2018 Phase 2 EUCTR2017-003272-31-NL Netherlands;
Sterile saline
James Gossage
2011 Phase 2 NCT01408030 United States;
Submucosal Bevacizumab
University of California, San Diego
2010 Phase 2 NCT01402531 United States;
THALIDOMIDE CELGENE*28CPS
OSPEDALE POLICLINICO S. MATTEO
2011 Phase 2 EUCTR2011-004096-36-IT Italy;
TIMOLOL MALEATE
Hospices Civils de Lyon
2015 Phase 2 EUCTR2015-000385-55-FR France;
Tacrolimus (Advagraf)
St. Antonius Hospital
2019 Phase 2 EUCTR2019-003585-40-NL Netherlands;
Tacrolimus capsule (low-dose)
Unity Health Toronto
2020 Phase 2 NCT04646356 Canada;
Tamoxifen
Rabin Medical Center
2005 Phase 2 NCT00375622 Israel;
Thalidomide
IRCCS Policlinico S. Matteo
2011 Phase 2 NCT01485224 Italy;
Northport Veterans Affairs Medical Center
2006 Phase 2 NCT00389935 United States;
Timolol Alcon collyre
Hospices Civils de Lyon
2015 Phase 2 EUCTR2015-000385-55-FR France;
Timolol Gel
Washington University School of Medicine
2019 Phase 2 NCT04139018 United States;
Timolol nasal spray
Hospices Civils de Lyon
2015 Phase 2 NCT02484716 France;
Topical timolol maleate
Unity Health Toronto
2013 - NCT01752049 Canada;
Tranexamic acid
University Hospital, Saarland
2002 Phase 3 NCT01031992 Germany;
Vit D
St. Paul's Hospital, Canada
2018 Phase 2 NCT03981562 Canada;